IMP Accountability

IMP Accountability

  1. lut 28, 2025

What Does the 'IMP Accountability’ Mean?

IMP Accountability refers to the process of tracking and documenting the lifecycle of an Investigational Medicinal Product (IMP) throughout a clinical trial. This includes maintaining accurate records of the receipt, storage, dispensing, administration, return, and disposal of the IMP at all stages of the study.

The purpose of IMP Accountability is to ensure regulatory compliance, patient safety, and data integrity in clinical research. It helps investigators and sponsors demonstrate that the IMP was handled correctly and administered only to eligible study participants in accordance with the approved protocol.

Why Is the 'IMP Accountability’ Important in Clinical Research?

IMP Accountability is crucial for maintaining the integrity and validity of clinical trial results. It ensures that the investigational product is used as intended, minimizing the risk of errors that could compromise patient safety or study outcomes. Proper accountability also helps detect and prevent potential fraud or misconduct in clinical research.

Furthermore, IMP Accountability is essential for regulatory compliance and auditing purposes. It provides a clear trail of evidence that can be reviewed by regulatory authorities to verify adherence to Good Clinical Practice (GCP) guidelines. This documentation is vital for the approval process of new drugs and therapies, demonstrating the reliability of the clinical trial data.

Good Practices and Procedures

  1. Implement a robust electronic tracking system with barcode scanning to record real-time IMP transactions, minimizing manual data entry errors and improving traceability.
  2. Establish a standardized reconciliation process, comparing dispensed IMPs against patient diaries and returned medication, to be performed at regular intervals throughout the trial.
  3. Develop a temperature excursion management protocol, including immediate notification procedures and decision trees for determining IMP usability after exposure to out-of-range conditions.
  4. Create a comprehensive chain of custody documentation system for IMP transfers between sites, central pharmacies, and storage facilities, including validated shipping methods and temperature monitoring.
  5. Implement a double-verification process for critical IMP accountability tasks, such as dose calculations, dispensing, and destruction, to reduce the risk of human error.

Related Terms

Read more

Radioisotopes in Medicine: Clinical Applications, Safety, and Regulatory Considerations

The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…

Poland Advances in Immuno-PET – A Sign of Growing Regional Leadership in Molecular Imaging

The National Institute of Oncology in Gliwice has launched a pioneering clinical study using a novel radiotracer for immuno-PET imaging.…

Axcellant at ASNC 2025: Insights, Collaboration, and Continued Focus on Nuclear Cardiology

The Axcellant team recently returned from Orlando, where we attended the 30th Annual Scientific Session and Exhibition of the American…